Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 240

1.

Clinicopathological characteristics and outcome of advanced ROS1-positive non-small cell lung cancer in Asian patients.

Kho CYX, Lim DW, Tan DSW, Tan WL, Rajasekaran T, Jain A, Toh CK, Ang MK, Tan EH, Ng QS.

Ann Oncol. 2019 Apr;30 Suppl 2:ii54. doi: 10.1093/annonc/mdz063.043. No abstract available.

2.

Genomic landscape of lung adenocarcinoma in East Asians.

Chen J, Yang H, Teo ASM, Amer LB, Sherbaf FG, Tan CQ, Alvarez JJS, Lu B, Lim JQ, Takano A, Nahar R, Lee YY, Phua CZJ, Chua KP, Suteja L, Chen PJ, Chang MM, Koh TPT, Ong BH, Anantham D, Hsu AAL, Gogna A, Too CW, Aung ZW, Lee YF, Wang L, Lim TKH, Wilm A, Choi PS, Ng PY, Toh CK, Lim WT, Ma S, Lim B, Liu J, Tam WL, Skanderup AJ, Yeong JPS, Tan EH, Creasy CL, Tan DSW, Hillmer AM, Zhai W.

Nat Genet. 2020 Feb;52(2):177-186. doi: 10.1038/s41588-019-0569-6. Epub 2020 Feb 3.

PMID:
32015526
3.

Genomic Outcomes of Haploid Induction Crosses in Potato (Solanum tuberosum L.).

Amundson KR, Ordoñez B, Santayana M, Tan EH, Henry IM, Mihovilovich E, Bonierbale M, Comai L.

Genetics. 2020 Feb;214(2):369-380. doi: 10.1534/genetics.119.302843. Epub 2019 Dec 23.

PMID:
31871130
4.

Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.

Tan AC, Lai GGY, Tan GS, Poon SY, Doble B, Lim TH, Aung ZW, Takano A, Tan WL, Ang MK, Tan BS, Devanand A, Too CW, Gogna A, Ong BH, Koh TPT, Kanesvaran R, Ng QS, Jain A, Rajasekaran T, Lim AST, Lim WT, Toh CK, Tan EH, Lim TKH, Tan DSW.

Lung Cancer. 2020 Jan;139:207-215. doi: 10.1016/j.lungcan.2019.11.022. Epub 2019 Nov 26.

PMID:
31835042
5.

Association of clinical factors with survival outcomes in laryngeal squamous cell carcinoma (LSCC).

Fong PY, Tan SH, Lim DWT, Tan EH, Ng QS, Sommat K, Tan DSW, Ang MK.

PLoS One. 2019 Nov 20;14(11):e0224665. doi: 10.1371/journal.pone.0224665. eCollection 2019.

6.

Activation of β-Catenin Cooperates with Loss of Pten to Drive AR-Independent Castration-Resistant Prostate Cancer.

Patel R, Brzezinska EA, Repiscak P, Ahmad I, Mui E, Gao M, Blomme A, Harle V, Tan EH, Malviya G, Mrowinska A, Loveridge CJ, Rushworth LK, Edwards J, Ntala C, Nixon C, Hedley A, Mackay G, Tardito S, Sansom OJ, Leung HY.

Cancer Res. 2020 Feb 1;80(3):576-590. doi: 10.1158/0008-5472.CAN-19-1684. Epub 2019 Nov 12.

7.

Phase II study of CC-486 (oral azacitidine) in previously treated patients with locally advanced or metastatic nasopharyngeal carcinoma.

Mesia R, Bossi P, Hansen AR, Hsieh CY, Licitra LF, Tan EH, Chen P, Miller J, Siu LL, Haddad RI.

Eur J Cancer. 2019 Dec;123:138-145. doi: 10.1016/j.ejca.2019.10.002. Epub 2019 Nov 4.

8.

Haploid Induction and Genome Instability.

Comai L, Tan EH.

Trends Genet. 2019 Nov;35(11):791-803. doi: 10.1016/j.tig.2019.07.005. Epub 2019 Aug 14. Review.

PMID:
31421911
9.

Publisher Correction: Methionine is a metabolic dependency of tumor-initiating cells.

Wang Z, Yip LY, Lee JHJ, Wu Z, Chew HY, Chong PKW, Teo CC, Ang HY, Peh KLE, Yuan J, Ma S, Choo LSK, Basri N, Jiang X, Yu Q, Hillmer AM, Lim WT, Lim TKH, Takano A, Tan EH, Tan DSW, Ho YS, Lim B, Tam WL.

Nat Med. 2019 Jun;25(6):1022. doi: 10.1038/s41591-019-0486-3.

PMID:
31114058
10.

Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer.

Park K, Bennouna J, Boyer M, Hida T, Hirsh V, Kato T, Lu S, Mok T, Nakagawa K, O'Byrne K, Paz-Ares L, Schuler M, Sibilot DM, Tan EH, Tanaka H, Wu YL, Yang JC, Zhang L, Zhou C, Märten A, Tang W, Yamamoto N.

Lung Cancer. 2019 Jun;132:126-131. doi: 10.1016/j.lungcan.2019.04.014. Epub 2019 Apr 10.

11.

Outcome-Based Critical Result Thresholds in the Adult Patient Population.

Tan EH, Yang Z, Li Y, Metz MP, Loh TP.

Am J Clin Pathol. 2019 Jul 5;152(2):177-184. doi: 10.1093/ajcp/aqz026.

PMID:
31067292
12.

Methionine is a metabolic dependency of tumor-initiating cells.

Wang Z, Yip LY, Lee JHJ, Wu Z, Chew HY, Chong PKW, Teo CC, Ang HY, Peh KLE, Yuan J, Ma S, Choo LSK, Basri N, Jiang X, Yu Q, Hillmer AM, Lim WT, Lim TKH, Takano A, Tan EH, Tan DSW, Ho YS, Lim B, Tam WL.

Nat Med. 2019 May;25(5):825-837. doi: 10.1038/s41591-019-0423-5. Epub 2019 May 6. Erratum in: Nat Med. 2019 Jun;25(6):1022.

PMID:
31061538
13.

Research funding impact and priority setting - advancing universal access and quality healthcare research in Malaysia.

Fun WH, Sararaks S, Tan EH, Tang KF, Chong DWQ, Low LL, Sapian RA, Ismail SA, Govind SK, Mahmud SH, Murad S.

BMC Health Serv Res. 2019 Apr 24;19(1):248. doi: 10.1186/s12913-019-4072-7.

14.

Rab7a and Mitophagosome Formation.

Tan EHN, Tang BL.

Cells. 2019 Mar 8;8(3). pii: E224. doi: 10.3390/cells8030224. Review.

15.

First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression.

Schuler M, Tan EH, O'Byrne K, Zhang L, Boyer M, Mok T, Hirsh V, Yang JC, Lee KH, Lu S, Shi Y, Kim SW, Laskin J, Kim DW, Arvis CD, Kölbeck K, Massey D, Märten A, Paz-Ares L, Park K.

J Cancer Res Clin Oncol. 2019 Jun;145(6):1569-1579. doi: 10.1007/s00432-019-02862-x. Epub 2019 Feb 19.

16.

Viability Screen of LOPAC1280 Reveals Tyrosine Kinase Inhibitor Tyrphostin A9 as a Novel Partner Drug for Artesunate Combinations To Target the Plasmodium falciparum Ring Stage.

Tong JX, Ang SEL, Tan EHN, Tan KSW.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e02389-18. doi: 10.1128/AAC.02389-18. Print 2019 Apr.

17.

Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.

Lai GGY, Lim TH, Lim J, Liew PJR, Kwang XL, Nahar R, Aung ZW, Takano A, Lee YY, Lau DPX, Tan GS, Tan SH, Tan WL, Ang MK, Toh CK, Tan BS, Devanand A, Too CW, Gogna A, Ong BH, Koh TPT, Kanesvaran R, Ng QS, Jain A, Rajasekaran T, Yuan J, Lim TKH, Lim AST, Hillmer AM, Lim WT, Iyer NG, Tam WL, Zhai W, Tan EH, Tan DSW.

J Clin Oncol. 2019 Apr 10;37(11):876-884. doi: 10.1200/JCO.18.00177. Epub 2019 Jan 24.

PMID:
30676858
18.

The Diet for Edible-Nest Swiftlets: Nutritional Composition and Cost of Life Stages of Megaselia scalaris Loew (Diptera: Phoridae) Bred on 3 Commercial Breeding Materials.

Ahmad H, Ong SQ, Tan EH.

Int J Insect Sci. 2019 Jan 9;11:1179543318823533. doi: 10.1177/1179543318823533. eCollection 2019.

19.

Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo).

Halmos B, Tan EH, Soo RA, Cadranel J, Lee MK, Foucher P, Hsia TC, Hochmair M, Griesinger F, Hida T, Kim E, Melosky B, Märten A, Carcereny E.

Lung Cancer. 2019 Jan;127:103-111. doi: 10.1016/j.lungcan.2018.10.028. Epub 2018 Nov 2.

20.

Relative criticalness of common laboratory tests for critical value reporting.

Yang Z, Tan EH, Li Y, Lim B, Metz MP, Loh TP.

J Clin Pathol. 2019 Apr;72(4):325-328. doi: 10.1136/jclinpath-2018-205549. Epub 2018 Dec 28.

PMID:
30593460
21.

Correction to: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases.

Tan WL, Ng QS, Lim C, Tan EH, Toh CK, Ang MK, Kanesvaran R, Jain A, Tan DSW, Lim DW.

BMC Cancer. 2018 Dec 24;18(1):1288. doi: 10.1186/s12885-018-5215-7.

22.

Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases.

Tan WL, Ng QS, Lim C, Tan EH, Toh CK, Ang MK, Kanesvaran R, Jain A, Tan DSW, Lim DW.

BMC Cancer. 2018 Dec 3;18(1):1198. doi: 10.1186/s12885-018-5110-2. Erratum in: BMC Cancer. 2018 Dec 24;18(1):1288.

23.

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.

Solomon BJ, Besse B, Bauer TM, Felip E, Soo RA, Camidge DR, Chiari R, Bearz A, Lin CC, Gadgeel SM, Riely GJ, Tan EH, Seto T, James LP, Clancy JS, Abbattista A, Martini JF, Chen J, Peltz G, Thurm H, Ou SI, Shaw AT.

Lancet Oncol. 2018 Dec;19(12):1654-1667. doi: 10.1016/S1470-2045(18)30649-1. Epub 2018 Nov 6. Erratum in: Lancet Oncol. 2019 Jan;20(1):e10.

PMID:
30413378
24.

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.

Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Faivre-Finn C, Reck M, Vansteenkiste J, Spigel DR, Wadsworth C, Melillo G, Taboada M, Dennis PA, Özgüroğlu M; PACIFIC Investigators.

N Engl J Med. 2018 Dec 13;379(24):2342-2350. doi: 10.1056/NEJMoa1809697. Epub 2018 Sep 25.

PMID:
30280658
25.
26.
27.

Concurrent-Adjuvant Chemoradiation Therapy for Stage III-IVB Nasopharyngeal Carcinoma-Exploration for Achieving Optimal 10-Year Therapeutic Ratio.

Ng WT, Tung SY, Lee V, Ngan RKC, Choi HCW, Chan LLK, Leung TW, Siu LL, Lu TX, Tan T, Tan EH, Sze HCK, Ng AWY, Yiu HHY, O'Sullivan B, Chappell R, Lee AWM.

Int J Radiat Oncol Biol Phys. 2018 Aug 1;101(5):1078-1086. doi: 10.1016/j.ijrobp.2018.04.069. Epub 2018 May 2.

PMID:
29885997
28.

Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates.

Simoni Y, Becht E, Fehlings M, Loh CY, Koo SL, Teng KWW, Yeong JPS, Nahar R, Zhang T, Kared H, Duan K, Ang N, Poidinger M, Lee YY, Larbi A, Khng AJ, Tan E, Fu C, Mathew R, Teo M, Lim WT, Toh CK, Ong BH, Koh T, Hillmer AM, Takano A, Lim TKH, Tan EH, Zhai W, Tan DSW, Tan IB, Newell EW.

Nature. 2018 May;557(7706):575-579. doi: 10.1038/s41586-018-0130-2. Epub 2018 May 16.

PMID:
29769722
29.

Human Innate Lymphoid Cell Subsets Possess Tissue-Type Based Heterogeneity in Phenotype and Frequency.

Simoni Y, Fehlings M, Kløverpris HN, McGovern N, Koo SL, Loh CY, Lim S, Kurioka A, Fergusson JR, Tang CL, Kam MH, Dennis K, Lim TKH, Fui ACY, Hoong CW, Chan JKY, Curotto de Lafaille M, Narayanan S, Baig S, Shabeer M, Toh SES, Tan HKK, Anicete R, Tan EH, Takano A, Klenerman P, Leslie A, Tan DSW, Tan IB, Ginhoux F, Newell EW.

Immunity. 2018 May 15;48(5):1060. doi: 10.1016/j.immuni.2018.04.028. No abstract available.

30.

Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials.

Wu YL, Sequist LV, Tan EH, Geater SL, Orlov S, Zhang L, Lee KH, Tsai CM, Kato T, Barrios CH, Schuler M, Hirsh V, Yamamoto N, O'Byrne K, Boyer M, Mok T, Peil B, Märten A, Chih-Hsin Yang J, Paz-Ares L, Park K.

Clin Lung Cancer. 2018 Jul;19(4):e465-e479. doi: 10.1016/j.cllc.2018.03.009. Epub 2018 Mar 17.

31.

A Decade of Never-smokers Among Lung Cancer Patients-Increasing Trend and Improved Survival.

Toh CK, Ong WS, Lim WT, Tan DS, Ng QS, Kanesvaran R, Seow WJ, Ang MK, Tan EH.

Clin Lung Cancer. 2018 Sep;19(5):e539-e550. doi: 10.1016/j.cllc.2018.03.013. Epub 2018 Mar 17.

PMID:
29627315
32.

Selective deletion of PPARβ/δ in fibroblasts causes dermal fibrosis by attenuated LRG1 expression.

Sng MK, Chan JSK, Teo Z, Phua T, Tan EHP, Wee JWK, Koh NJN, Tan CK, Chen JP, Pal M, Tong BMK, Tnay YL, Ng XR, Zhu P, Chiba S, Wang X, Wahli W, Tan NS.

Cell Discov. 2018 Apr 3;4:15. doi: 10.1038/s41421-018-0014-5. eCollection 2018.

33.

Detection of Chromothripsis in Plants.

Henry IM, Comai L, Tan EH.

Methods Mol Biol. 2018;1769:119-132. doi: 10.1007/978-1-4939-7780-2_8.

PMID:
29564821
34.

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.

Garassino MC, Cho BC, Kim JH, Mazières J, Vansteenkiste J, Lena H, Corral Jaime J, Gray JE, Powderly J, Chouaid C, Bidoli P, Wheatley-Price P, Park K, Soo RA, Huang Y, Wadsworth C, Dennis PA, Rizvi NA; ATLANTIC Investigators.

Lancet Oncol. 2018 Apr;19(4):521-536. doi: 10.1016/S1470-2045(18)30144-X. Epub 2018 Mar 12.

PMID:
29545095
35.

The validation study on a three-dimensional burn estimation smart-phone application: accurate, free and fast?

Cheah AKW, Kangkorn T, Tan EH, Loo ML, Chong SJ.

Burns Trauma. 2018 Feb 27;6:7. doi: 10.1186/s41038-018-0109-0. eCollection 2018.

36.

ROS release by PPARβ/δ-null fibroblasts reduces tumor load through epithelial antioxidant response.

Tan EHP, Sng MK, How ISB, Chan JSK, Chen J, Tan CK, Wahli W, Tan NS.

Oncogene. 2018 Apr;37(15):2067-2078. doi: 10.1038/s41388-017-0109-8. Epub 2018 Jan 25.

37.

Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC.

Tan EH, Lim WT, Ahn MJ, Ng QS, Ahn JS, Shao-Weng Tan D, Sun JM, Han M, Payumo FC, McKee K, Yin W, Credi M, Agarwal S, Jac J, Park K.

Clin Pharmacol Drug Dev. 2018 Jun;7(5):532-542. doi: 10.1002/cpdd.427. Epub 2018 Jan 18.

38.

Elucidating the genomic architecture of Asian EGFR-mutant lung adenocarcinoma through multi-region exome sequencing.

Nahar R, Zhai W, Zhang T, Takano A, Khng AJ, Lee YY, Liu X, Lim CH, Koh TPT, Aung ZW, Lim TKH, Veeravalli L, Yuan J, Teo ASM, Chan CX, Poh HM, Chua IML, Liew AA, Lau DPX, Kwang XL, Toh CK, Lim WT, Lim B, Tam WL, Tan EH, Hillmer AM, Tan DSW.

Nat Commun. 2018 Jan 15;9(1):216. doi: 10.1038/s41467-017-02584-z.

39.

Systematic review and meta-analysis of algorithms used to identify drug-induced liver injury (DILI) in health record databases.

Tan EH, Low EXS, Dan YY, Tai BC.

Liver Int. 2018 Apr;38(4):742-753. doi: 10.1111/liv.13646. Epub 2017 Dec 16.

PMID:
29193566
40.

Analysis of Nkx3.1:Cre-driven Erk5 deletion reveals a profound spinal deformity which is linked to increased osteoclast activity.

Loveridge CJ, van 't Hof RJ, Charlesworth G, King A, Tan EH, Rose L, Daroszewska A, Prior A, Ahmad I, Welsh M, Mui EJ, Ford C, Salji M, Sansom O, Blyth K, Leung HY.

Sci Rep. 2017 Oct 16;7(1):13241. doi: 10.1038/s41598-017-13346-8.

41.

Improved Survival of Advanced Lung Cancer in Singapore Over the Past Decade.

Toh CK, Ong WS, Tan DS, Ng QS, Kanesvaran R, Fong KW, Ang MK, Tan EH, Lim WT.

Ann Acad Med Singapore. 2017 Sep;46(9):333-338.

42.

Long noncoding RNA EGFR-AS1 mediates epidermal growth factor receptor addiction and modulates treatment response in squamous cell carcinoma.

Tan DSW, Chong FT, Leong HS, Toh SY, Lau DP, Kwang XL, Zhang X, Sundaram GM, Tan GS, Chang MM, Chua BT, Lim WT, Tan EH, Ang MK, Lim TKH, Sampath P, Chowbay B, Skanderup AJ, DasGupta R, Iyer NG.

Nat Med. 2017 Oct;23(10):1167-1175. doi: 10.1038/nm.4401. Epub 2017 Sep 18.

PMID:
28920960
43.

Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Wadsworth C, Melillo G, Jiang H, Huang Y, Dennis PA, Özgüroğlu M; PACIFIC Investigators.

N Engl J Med. 2017 Nov 16;377(20):1919-1929. doi: 10.1056/NEJMoa1709937. Epub 2017 Sep 8.

44.

Mutation of Arabidopsis SMC4 identifies condensin as a corepressor of pericentromeric transposons and conditionally expressed genes.

Wang J, Blevins T, Podicheti R, Haag JR, Tan EH, Wang F, Pikaard CS.

Genes Dev. 2017 Aug 1;31(15):1601-1614. doi: 10.1101/gad.301499.117. Epub 2017 Sep 7.

45.

Downstream drug product processing of itraconazole nanosuspension: Factors influencing tablet material properties and dissolution of compacted nanosuspension-layered sugar beads.

Tan EH, Parmentier J, Low A, Möschwitzer JP.

Int J Pharm. 2017 Oct 30;532(1):131-138. doi: 10.1016/j.ijpharm.2017.08.107. Epub 2017 Aug 30.

PMID:
28859940
46.

Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.

Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, Ou SI, Pérol M, Dziadziuszko R, Rosell R, Zeaiter A, Mitry E, Golding S, Balas B, Noe J, Morcos PN, Mok T; ALEX Trial Investigators.

N Engl J Med. 2017 Aug 31;377(9):829-838. doi: 10.1056/NEJMoa1704795. Epub 2017 Jun 6.

47.

Increased T-cell Infiltration Elicited by Erk5 Deletion in a Pten-Deficient Mouse Model of Prostate Carcinogenesis.

Loveridge CJ, Mui EJ, Patel R, Tan EH, Ahmad I, Welsh M, Galbraith J, Hedley A, Nixon C, Blyth K, Sansom O, Leung HY.

Cancer Res. 2017 Jun 15;77(12):3158-3168. doi: 10.1158/0008-5472.CAN-16-2565. Epub 2017 May 17.

48.

Hydration effects on the efficacy of the Epidermal growth factor receptor kinase inhibitor afatinib.

Kannan S, Pradhan MR, Tiwari G, Tan WC, Chowbay B, Tan EH, Tan DS, Verma C.

Sci Rep. 2017 May 8;7(1):1540. doi: 10.1038/s41598-017-01491-z.

49.

A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer.

Soh SX, Siddiqui FJ, Allen JC, Kim GW, Lee JC, Yatabe Y, Soda M, Mano H, Soo RA, Chin TM, Ebi H, Yano S, Matsuo K, Niu X, Lu S, Isobe K, Lee JH, Yang JC, Zhao M, Zhou C, Lee JK, Lee SH, Lee JY, Ahn MJ, Tan TJ, Tan DS, Tan EH, Ong ST, Lim WT.

Oncotarget. 2017 Jun 20;8(25):41474-41486. doi: 10.18632/oncotarget.17102. Review.

50.

Management of epidermal growth factor receptor tyrosine kinase inhibitor-related cutaneous and gastrointestinal toxicities.

Aw DC, Tan EH, Chin TM, Lim HL, Lee HY, Soo RA.

Asia Pac J Clin Oncol. 2018 Feb;14(1):23-31. doi: 10.1111/ajco.12687. Epub 2017 May 2. Review.

PMID:
28464435

Supplemental Content

Loading ...
Support Center